Preface 2011 {#Sec1}
============

We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2011, was published here, despite some delay. The registry complies with the Act for the Protection of Personal Information. The encryption with an HASH function is used for anonymity in an unlinkable fashion.

We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2011. Japanese Classification of Esophageal Cancer 10th and UICC TNM Classification 7th were used for cancer staging according to the subjected year. A total of 6993 cases were registered from 300 institutions in Japan. Tumor locations were cervical: 4.5%, upper thoracic: 13.0%, middle thoracic: 47.8%, lower thoracic: 27.2%, and EG junction: 7.1%. Superficial carcinomas (Tis, T1a, and T1b) were 36.4%. For the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 88.3 and 5.3%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, or esophagectomy were 86.0, 28.1, 26.5, and 54.5%, respectively. The endoscopic submucosal dissection accounted for 78.1% of endoscopic resection. Esophagectomy was performed in 4147 cases. Concerning the approach used for esophagectomy, 33.5% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.65% and the hospital mortality was 3.76%. The 5-year survival rate of patients with pStage IV in UICC classification (including patients with supraclavicular node metastasis) was better than that of patients with pStage IVb in JES classification (not including patients with supraclavicular node metastasis).

We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2011 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.
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I. Clinical factors of esophageal cancer patients treated in 2011 {#Sec3}
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Institution-registered cases in 2011 {#Sec4}
------------------------------------

InstitutionAgeo Central General HospitalAichi Cancer CenterAichi Medical University HospitalAizawa HospitalAkita Kouseiren Hiraga HospitalAkita University HospitalArao Municipal HospitalAsahikawa Medical College HospitalAsahikawa-Kosei General HospitalChiba Cancer CenterChiba Medical CenterChiba Prefectural Sawara HospitalChiba University HospitalChigasaki Municipal HospitalDokkyo Medical University HospitalDokkyo Medical University Saitama Medical CenterEiju General HospitalFoundation for Detection of Early Gastric CarcinomaFuchu HospitalFujioka General HospitalFujisawa Shounandai HospitalFujita Health UniversityFukui Prefectural HospitalFukui University HospitalFukui-ken Saiseikai HospitalFukuoka Dental College and Dental HospitalFukuoka Saiseikai General HospitalFukuoka University Chikushi HospitalFukuoka University HospitalFukuoka Wajiro HospitalFukushima Medical University HospitalFukuyama City HospitalFussa HospitalGifu Prefectural General Medical CenterGifu University HospitalGunma Central General HospitalGunma Prefectural Cancer CenterGunma University HospitalGunmaken Saiseikai Maebashi HospitalHachinohe City HospitalHakodate Goryokaku HospitalHakodate National HospitalHamamatsu University School of Medicine, University HospitalHannan Chuo HospitalHeartlife HospitalHigashiosaka City Medical CenterHino Memorial HospitalHino Municipal HospitalHiratsuka City HospitalHiratsuka Kyosai HospitalHirosaki University HospitalHiroshima City Asa HospitalHiroshima City Hiroshima Citizens HospitalHiroshima Red Cross Hospital and Atomic-bomb Survivors HospitalHiroshima University HospitalHitachi General HospitalHofu Institute of GastroenterologyHokkaido University HospitalHyogo Cancer CenterHyogo College of MedicineHyogo Prefectural Nishinomiya HospitalIbaraki Prefectural Central HospitalIizuka HospitalImazu Surgical ClinicInazawa City HospitalInternational University of Health and Welfare HospitalInternational Goodwill HospitalIsehara Kyodo HospitalIshikawa Prefectural Central HospitalIwakuni Medical CenterIwate Medical University HospitalIwate Prefectural Chubu HospitalIwate Prefectural Isawa HospitalJapanese Red Cross Fukui HospitalJapanese Red Cross Ishinomaki HospitalJapanese Red Cross Kyoto Daini HospitalJapanese Red Cross Nagaoka HospitalJapanese Red Cross Okayama HospitalJCHO Kyushu HospitalJCHO Osaka HospitalJichi Medical University HospitalJichi Medical University Saitama Medical CenterJuntendo University HospitalJuntendo University Shizuoka HospitalKagawa Prefectural Central HospitalKagawa Rosai HospitalKagawa University HospitalKagoshima Kenritsu Satsunan HospitalKagoshima University HospitalKameda General HospitalKanagawa Cancer CenterKanazawa Medical University HospitalKanazawa University HospitalKansai Medical University HospitalKansai Rosai HospitalKasamatsu HospitalKashiwa Kousei General HospitalKawasaki Medical School HospitalKawasaki Medical School Kawasaki HospitalKawasaki Municipal Ida HospitalNara Hospital Kinki University Faculty of MedicineNara Medical University HospitalNational Cancer Center HospitalNational Cancer Center Hospital EastNational Center for Global Health and MedicineNational Defense Medical College HospitalNational Hospital Organization Beppu Medical CenterNational Hospital Organization Chiba Medical CenterNational Hospital Organization Chiba-East-HospitalNational Hospital Organization Fukuoka-higashi Medical CenterNational Hospital Organization Hokkaido Cancer CenterNational Hospital Organization Iwakuni Medical CenterNational Hospital Organization Kanmon Medical CenterNational Hospital Organization Kure Medical CenterNational Hospital Organization Kyoto Medical CenterNational Hospital Organization Kyushu Cancer CenterNational Hospital Organization Matsumoto Medical CenterNational Hospital Organization Nagasaki Medical CenterNational Hospital Organization Nagoya Medical CenterNational Hospital Organization Okayama Medical CenterNational Hospital Organization Osaka National HospitalNational Hospital Organization Tokyo Medical CenterNiigata Cancer Center HospitalNiigata City General HospitalNiigata Prefectural Shibata HospitalNiigata University Medical and Dental HospitalNikko Memorial HospitalNippon Medical School Chiba Hokusoh HospitalNippon Medical School HospitalNippon Medical School Musashi Kosugi HospitalNippon Medical School Tama Nagayama HospitalNishi-Kobe Medical CenterNishinomiya Municipal Central HospitalNTT WEST Osaka HospitalNumazu City HospitalObihiro Kousei General HospitalOgaki Municipal HospitalOhta General Hospital Foundation Ohta Nishinouchi HospitalOita Red Cross HospitalOita University HospitalOkayama Saiseikai General HospitalOkayama University HospitalOsaka City University HospitalOsaka Hospital of Japan Seafarers relief AssociationOsaka International Cancer InstituteOsaka Medical College HospitalOsaka Police HospitalOsaka Prefectural Hospital Organization Osaka General Medical CenterOsaka Red Cross HospitalOsaka University HospitalOtsu City HospitalOtsu Red Cross HospitalRinku General Medical CenterRyukyu University HospitalSaga University HospitalSaga-ken Medical Center KoseikanSaiseikai Fukushima General HospitalSaiseikai Kyoto HospitalSaiseikai Utsunomiya HospitalSaiseikai Yahata General HospitalSaitama Cancer CenterSaitama City HospitalSaitama Medical CenterSaitama Medical University HospitalSaitama Medical University Saitama Medical CenterSakai City Medical CenterSaku Central HospitalSanin Rosai HospitalSano Kousei General HospitalSato ClinicSendai City HospitalSendai Medical CenterShiga University of Medical Science HospitalShikoku Cancer CenterShimane University HospitalShimizu Welfare HospitalShin Beppu HospitalShinko HospitalShizuoka Cancer CenterShizuoka City Shizuoka HospitalShizuoka General HospitalShowa University Fujigaoka HospitalShowa University HospitalShowa University Koto-Toyosu HospitalSocial Insurance Omuta Tenryo HospitalSocial Insurance Tagawa HospitalSt. Marianna University School of Medical HospitalSt. Luke's International HospitalSugita Genpaku Memorial Obama Municipal HospitalSuita Municipal HospitalTakasago Municipal HospitalTeikyo University Chiba Medical CenterTeikyo University HospitalTenri HospitalThe Cancer Institute Hospital of JFCRThe Jikei University Daisan HospitalThe Jikei University HospitalThe Research Center Hospital for Charged Particle Therapy of NIRSTochigi Cancer CenterToho University Ohashi Medical CenterToho University Omori Medical CenterToho University Sakura Medical CenterTohoku Kosai HospitalTohoku University HospitalTokai University Hachioji HospitalTokai University HospitalTokai University Tokyo HospitalTokushima Red Cross HospitalTokushima University HospitalTokuyama Central HospitalTokyo Dental College Ichikawa General HospitalTokyo Medical and Dental University HospitalTokyo Medical University HospitalTokyo Medical University Ibaraki Medical CenterTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyo Metropolitan Health and Medical Corporation Toshima HospitalTokyo Metropolitan Tama Medical CenterTokyo Saiseikai Central HospitalTokyo University HospitalTokyo Women's Medical University HospitalTokyo Women's Medical University Medical Center EastTokyo Women's Medical University Yachiyo Medical CenterTonan HospitalTone Chuo HospitalToranomon HospitalTottori Prefectural Central HospitalTottori University HospitalToyama Prefectural Central HospitalToyama University HospitalToyonaka Municipal HospitalTsuchiura Kyodo HospitalTsukuba University HospitalTsuruoka Municipal Shonai HospitalUniversity Hospital, Kyoto Prefectural University of MedicineUniversity of Miyazaki HospitalUrasoe General HospitalWakayama Medical University HospitalYamagata Prefectural and Sakata Municipal Hospital OrganizationYamagata Prefectural Central HospitalYamagata Prefectural Shinjo HospitalYamagata University HospitalYamaguchi University HospitalYamaguchi-ken Saiseikai Shimonoseki General HospitalYamanashi Prefectural Central HospitalYamanashi University HospitalYao Municipal HospitalYokohama Chuo HospitalYokohama City Municipal HospitalYokohama City University Medical CenterYokohama Rosai Hospital(Total 300 institutions)

Patient background {#Sec5}
------------------

Table 1Age and genderAgeMaleFemaleCases (%)≤ 29415 (0.1%)30 -- 3922830 (0.4%)40 -- 4914247189 (2.7%)50 -- 598781731051 (15.0%)60 -- 6925313602891 (41.3%)70 -- 7919413332274 (32.5%)80 -- 8944290532 (7.6%)90--13821 (0.3%)Total597310206993 Table 2Primary treatmentTreatmentsCases (%)Surgery4236 (60.7%) Esophagectomy4147 (59.4%) Palliative surgery89 (1.3%)Chemotherapy/radiotherapy1549 (22.2%)Endoscopic treatment1198 (17.2%)Total6983 Table 3Tumor locationLocation of tumorEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)Esophagectomy (%)Palliative surgery (%)Cervical33 (2.8%)127 (3.1%)4 (4.5%)147 (9.5%)311 (4.5%)Upper thoracic116 (9.7%)517 (12.5%)18 (20.2%)256 (16.5%)907 (13.0%)Middle thoracic687 (57.3%)1873 (45.2%)46 (51.7%)732 (47.3%)3338 (47.8%)Lower thoracic296 (24.7%)1235 (29.8%)20 (22.5%)345 (22.3%)1896 (27.2%)EG41 (3.4%)300 (7.2%)036 (2.3%)377 (5.4%)E = G9 (0.8%)47 (1.1%)01 (0.1%)57 (0.8%)GE5 (0.4%)40 (1.0%)1 (1.1%)2 (0.1%)48 (0.7%)Unknown11 (0.9%)8 (0.2%)030 (1.9%)49 (0.7%)Total119841478915496983*E* esophageal, *G* gastric Table 4Histologic types of biopsy specimensHistologic typesCases (%)Squamous cell carcinoma6164 (88.3%) Squamous cell carcinoma4369 (62.6%) Well differentiated378 (5.4%) Moderately differentiated1054 (15.1%) Poorly differentiated363 (5.2%)Adenocarcinoma281 (4.0%)Barrett's adenocarcinoma90 (1.3%)Adenosquamous carcinoma15 (0.2%)Mucoepidermoid carcinoma4 (0.1%)Basaloid carcinoma35 (0.5%)Neuroendocrine cell tumor26 (0.4%)Undifferentiated carcinoma8 (0.1%)Sarcoma6 (0.1%)Malignant melanoma19 (0.3%)Carcinosarcoma22 (0.3%)GIST7 (0.1%)Other tumors92 (1.3%)Unknown214 (3.1%)Total6983 Table 5Depth of tumor invasion, cT (UICC TNM 7th)cTCases (%)cTX71 (1.0%)cT010 (0.1%)cTis198 (2.8%)cT1a1051 (15.1%)cT1b1292 (18.5%)cT2905 (13.0%)cT32408 (34.5%)cT4a384 (5.5%)cT4b530 (7.6%)Unknown134 (1.9%)Total6983 Table 6Lymph node metastasis, cN (UICC TNM 7th)cNCases (%)cNX187 (2.7%)cN03195 (45.8%)cN11864 (26.7%)cN21199 (17.2%)cN3459 (6.6%)Unknown79 (1.1%)Total6983 Table 7Distant metastasis, cM (UICC TNM 7th)cMCases (%)cM06128 (87.8%)cM1722 (10.3%)Unknown133 (1.9%)Total6983 Table 8Clinical stage (UICC TNM 7th)Clinical stageEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)Esophagectomy (%)Palliative surgery (%)Stage 0151 (12.6%)15 (0.4%)07 (0.5%)173 (2.5%)Stage IA809 (67.5%)937 (22.6%)1 (1.1%)161 (10.4%)1908 (27.3%)Stage IB2 (0.2%)363 (8.8%)1 (1.1%)58 (3.7%)424 (6.1%)Stage IIA3 (0.3%)419 (10.1%)3 (3.4%)60 (3.9%)485 (6.9%)Stage IIB4 (0.3%)470 (11.3%)1 (1.1%)63 (4.1%)538 (7.7%)Stage IIIA10 (0.8%)898 (21.7%)14 (15.7%)147 (9.5%)1069 (15.3%)Stage IIIB6 (0.5%)456 (11.0%)9 (10.1%)99 (6.4%)570 (8.2%)Stage IIIC32 (2.7%)292 (7.0%)27 (30.3%)390 (25.2%)741 (10.6%)Stage IV40 (3.3%)165 (4.0%)25 (28.1%)434 (28.0%)664 (9.5%)Unknown141 (11.8%)132 (3.2%)8 (9.0%)130 (8.4%)411 (5.9%)Total119841478915496983

II. Results of endoscopically treated patients in 2011 {#Sec6}
======================================================

Table 9Details of endoscopic treatment for curative intentTreatment detailsCases (%)EMR190 (17.9%)EMR + YAG laser13 (1.2%)ESD829 (78.1%)ESD + EMR5 (0.5%)ESD + PDT0ESD + YAG laser5 (0.5%)PDT2 (0.2%)YAG laser18 (1.7%)Total1062*EMR* endoscopic mucosal resection, *ESD* endoscopic submucosal dissection, *YAG* yttrium aluminum garnet, *PDT* photodynamic therapy Table 10Complications of EMR/ESDComplications of EMR/ESDCases (%)None969 (93.0%)Perforation13 (1.2%)Bleeding3 (0.3%)Mediastinitis3 (0.3%)Stenosis49 (4.7%)Others4 (0.4%)Total1042 Table 11Pathological depth of tumor invasion of EMR/ESD specimensPathological depth of tumor invasion (pT)Cases (%)pTX3 (0.3%)pT07 (0.7%)pTis201 (19.3%)pT1a703 (67.5%)pT1b114 (10.9%)pT23 (0.3%)Unknown11 (1.1%)Total1042 Fig. 1Survival of patients treated with EMR/ESD Fig. 2Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion (pT) Fig. 3Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

III. Results in patients treated with chemotherapy and/or radiotherapy in 2011 {#Sec7}
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Table 12Dose of irradiation (non-surgically treated cases)Dose of irradiation (Gy)DefinitivePalliative (%)Recurrence (%)Others (%)Unknown (%)Total (%)Radiation alone (%)Chemoradiotherapy (%)− 296 (3.5%)13 (1.7%)32 (10.9%)02 (5.7%)053 (4.1%)30--394 (2.3%)17 (2.2%)40 (13.6%)02 (5.7%)063 (4.9%)40--498 (4.6%)33 (4.2%)34 (11.6%)010 (28.6%)085 (6.6%)50--5929 (16.8%)177 (22.7%)71 (24.1%)1 (25.0%)11 (31.4%)1 (50.0%)290 (22.5%)60--69116 (67.1%)516 (66.1%)108 (36.7%)3 (75.0%)9 (25.7%)0752 (58.3%)70--9 (5.2%)12 (1.5%)3 (1.0%)01 (2.9%)025 (2.2%)Unknown1 (0.6%)13 (1.7%)6 (2.0%)001 (50.0%)21 (1.6%)Total17378129443521289Median (min--max)60.0 (4.4--70.0)60.0 (1.8--120.0)50.4 (3.6--159.0)60.0 (50.0--61.2)50.0 (21.6--109.0)54.0 (54.0--54.0)60.0 (1.8--105.0) Table 13Dose of irradiation (surgically treated cases)Dose of irradiation (Gy)Preoperative irradiation (%)Postoperative irradiation (%)--295 (2.2%)3 (6.0%)30--3939 (17.1%)040--49156 (68.4%)8 (16.0%)50--5915 (6.6%)15 (30.0%)60--696 (2.6%)15 (30.0%)70--1 (0.4%)0Unknown6 (2.6%)9 (18.0%)Total22850Median (min--max)40.0 (1.8--70.0)50.4 (2.0--66.0) Fig. 4Survival of patients treated with chemotherapy and/or radiotherapy Fig. 5Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th) Fig. 6Survival of patients underwent radiotherapy alone according to clinical stage (UICC TNM 7th)

IV. Results in patients who underwent esophagectomy in 2011 {#Sec8}
===========================================================

Table 14Treatment modalities of esophagectomyTreatmentsCases (%)Esophagectomy alone1699 (41.2%)Esophagectomy + endoscopic treatment89 (2.2%)Esophagectomy + chemoradiotherapy590 (14.3%) Concurrent chemoradiotherapy370 (9.0%) Other220 (5.3%)Esophagectomy + chemoradiotherapy + endoscopic treatment21 (0.5%)Esophagectomy + chemotherapy1657 (40.2%) Preoperative1295 (31.4%) Postoperative198 (4.8%) Preoperative and postoperative57 (1.4%) Recurrence107 (2.6%) Other20 (0.5%)Esophagectomy + chemotherapy + endoscopic treatment1 (0.0%)Esophagectomy + radiotherapy67 (1.6%) Preoperative17 (0.4%) Postoperative13 (0.3%) Recurrence5 (0.1%) Other32 (0.8%)Esophagectomy + radiotherapy + endoscopic treatment3 (0.1%)Total4127 Table 15Tumor locationLocationsCases (%)Cervical127 (3.1%)Upper thoracic517 (12.5%)Middle thoracic1873 (45.2%)Lower thoracic1235 (29.8%)E \> G300 (7.2%)E = G47 (1.1%)G \> E40 (1.0%)Unknown8 (0.2%)Total lesions4147 Table 16Approaches to tumor resectionApproachesCases (%)Cervical approach96 (2.3%)Right thoracic3459 (83.4%)Left thoracic67 (1.6%)Left thoracoabdominal72 (1.7%)Abdominal172 (4.1%)Transhiatal thoracic esophagectomy51 (1.2%)Transhiatal lower esophagectomy82 (2.0%)Sternotomy9 (0.2%)Others33 (0.8%)Unknown106 (2.6%)Total4147Thoracic includes thoracotomy and thoracoscopic. Abdominal includes laparotomy and laparoscopic Table 17Video-assisted surgeryVideo-assisted surgeryCases (%)None2389 (57.6%)Thoracoscopy768 (18.5%)Thoracoscopy + Laparoscopy605 (14.6%)Thoracoscopy + Laparoscopy + Mediastinoscopy15 (0.4%)Thoracoscopy + Mediastinoscopy2 (0.0%)Laparoscopy201 (4.8%)Laparoscopy + Mediastinoscopy14 (0.3%)Laparoscopy + Other2 (0.0%)Mediastinoscopy21 (0.5%)Others4 (0.1%)Total4147 Table 18Fields of lymph node dissection according to the location of the tumorField of lymphadenectomyCervicalUpper thoracicMiddle thoracicLower thoracicE \> GE = GG \> EUnknownTotalNone10 (8.6%)13 (3.2%)59 (3.5%)28 (2.7%)13 (5.4%)2 (25.0%)125 (3.5%)C36 (31.0%)10 (2.4%)20 (1.2%)3 (0.3%)1 (0.4%)70 (2.0%)C + UM21 (18.1%)6 (1.5%)3 (0.2%)1 (0.1%)31 (0.9%)C + UM + MLM2 (1.7%)12 (2.9%)28 (1.7%)12 (1.1%)1 (3.7%)55 (1.5%)C + UM + MLM + A27 (23.3%)257 (62.5%)800 (47.9%)367 (34.8%)26 (10.8%)6 (15.8%)1 (12.5%)1484 (41.6%)C + UM + MLM + A+OT1 (0.1%)1 (0.0%)C + UM + A2 (1.7%)1 (0.2%)2 (0.1%)2 (0.2%)7 (0.2%)C + MLM1 (0.1%)1 (0.0%)C + MLM + A3 (2.6%)1 (0.2%)7 (0.4%)3 (0.3%)14 (0.4%)C + A1 (0.9%)2 (0.5%)4 (0.2%)2 (0.2%)1 (0.4%)10 (0.3%)UM4 (3.4%)3 (0.7%)5 (0.3%)3 (0.3%)15 (0.4%)UM + MLM1 (0.9%)7 (1.7%)29 (1.7%)12 (1.1%)1 (0.4%)1 (12.5%)51 (1.4%)UM + MLM + A3 (2.6%)75 (18.2%)627 (37.6%)478 (45.4%)56 (23.2%)5 (13.2%)1 (3.7%)1 (12.5%)1246 (35.0%)UM + A1 (0.9%)4 (1.0%)2 (0.1%)2 (0.2%)2 (0.8%)11 (0.3%)MLM3 (0.7%)10 (0.6%)14 (1.3%)3 (1.2%)30 (0.8%)MLM + A1 (0.9%)7 (1.7%)34 (2.0%)102 (9.7%)108 (44.8%)23 (60.5%)17 (63.0%)292 (8.2%)A1 (0.9%)6 (1.5%)22 (1.3%)12 (1.1%)28 (11.6%)3 (7.9%)8 (29.6%)1 (12.5%)81 (2.3%)Unknown3 (2.6%)4 (1.0%)16 (1.0%)12 (1.1%)2 (0.8%)1 (2.6%)2 (25.0%)40 (1.1%)Total11641116691054241382783564*C* bilateral cervical nodes, *UM* upper mediastinal nodes, *MLM* middle--lower mediastinal nodes, *A* abdominal nodes Table 19Reconstruction routeReconstruction routeCases (%)None56 (1.4%)Subcutaneous384 (9.3%)Retrosternal1437 (34.7%)Posterior mediastinal1715 (41.4%)Intrathoracic419 (10.1%)Cervical35 (0.8%)Others34 (0.8%)Unknown67 (1.6%)Total4147 Table 20Organs used for reconstructionOrgans used for reconstructionCases (%)None76 (1.8%)Whole stomach63 (1.5%)Gastric tube3508 (83.6%)Jejunum255 (6.1%)Free jejunum76 (1.8%)Colon127 (3.0%)Free colon13 (0.3%)Skin graft1Others14 (0.3%)Unknown63 (1.5%)Total organs4196Total cases4147 Table 21Histological classificationHistological classificationCases (%)Squamous cell carcinoma3502 (84.4%) Squamous cell carcinoma732 (17.7%) Well differentiated645 (15.6%) Moderately differentiated1630 (39.3%) Poorly differentiated495 (11.9%)Adenocarcinoma210 (5.1%)Barrett's adenocarcinoma78 (1.9%)Adenosquamous carcinoma31 (0.7%)Mucoepidermoid carcinoma3 (0.1%)Adenoid cystic carcinoma2 (0.0%)Basaloid carcinoma81 (2.0%)Neuroendocrine cell tumor15 (0.4%)Undifferentiated carcinoma8 (0.2%)Other carcinoma9 (0.2%)Carcinosarcoma29 (0.7%)Malignant melanoma16 (0.4%)GIST6 (0.1%)Other39 (0.9%)Unknown118 (2.8%)Total4147 Table 22Depth of tumor invasion, pT (JES 10th)pT categoryCases (%)pTX57 (1.4%)pT0128 (3.1%)pTis31 (0.7%)pT1a435 (10.5%)pT1b1070 (25.8%)pT2516 (12.4%)pT31576 (38.0%)pT424 (0.6%)pT4a93 (2.2%)pT4b89 (2.1%)Unknown128 (3.1%)Total4147 Table 23Pathological grading of lymph node metastasis, pN (JES 10th)Lymph node metastasisCases (%)pN01970 (47.5%)pN1616 (14.9%)pN2949 (22.9%)pN3323 (7.8%)pN4209 (5.0%)Unknown80 (1.9%)Total4147 Table 24Pathological findings of lymph node metastasis, pN (UICC 7th)Lymph node metastasisCases (%)pN01871 (45.1%)pN1 (1--2)1165 (28.1%)pN2 (3--6)659 (15.9%)pN3 (7--)366 (8.8%)Unknown86 (2.1%)Total4147Regional lymph nodes are different in JES 10th and UICC 7thData for Tables [23](#Tab23){ref-type="table"} and [24](#Tab24){ref-type="table"} were analyzed from different variables in the registration application Table 25Pathological findings of distant organ metastasis, pM (JES 10th)Distant metastasisCases (%)pMX195 (4.7%)pM03886 (93.7%)pM166 (1.6%)Total4147 Table 26Residual tumorResidual tumorCases (%)RX147 (3.5%)R03624 (87.4%)R1219 (5.3%)R2157 (3.8%)Total4147 Table 27Causes of deathCause of deathCases (%)Death due to recurrence1223 (71.2%)Death due to other cancer71 (4.1%)Death due to other disease (rec+)42 (2.4%)Death due to other disease (rec−)239 (13.9%)Death due to other disease (rec?)9 (0.5%)Operative death\*27 (1.6%)Postoperative hospital death\*\*55 (3.2%)Unknown51 (3.0%)Total of death cases1717rec: recurrence\*Operative death means death within 30 days after operation in or out of hospital\*\*Hospital death is defined as death during the same hospitalization, regardless of department at time of deathOperative mortality after esophagectomy: 0.65%Hospital mortality after esophagectomy: 3.76%![](10388_2018_614_Figa_HTML.gif){#d29e5590} Fig. 7Survival of patients who underwent esophagectomy Fig. 8Survival of patients who underwent esophagectomy according to clinical stage (JES 10th) Fig. 9Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th) Fig. 10Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th) Fig. 11Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th) Fig. 12Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th) Fig. 13Survival of patients who underwent esophagectomy according to pathological stage (JES 10th) Fig. 14Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th) Fig. 15Survival of patients who underwent esophagectomy according to residual tumor (R)

These data were first made available on March 2018, as the Comprehensive Registry of Esophageal Cancer in Japan, 2011. Not all the pages are reprinted here.

The authors were members of the Registration Committee for Esophageal Cancer, the Japan Esophageal Society, and made great contributions to the preparation of this material.

A correction to this article is available online at <https://doi.org/10.1007/s10388-018-0624-x>.

**Change history**

6/12/2018

In the original publication of the article, the below name of institutions were not included in the table of Institution-registered cases in 2011.
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